Teva achieves full investment-grade status after S&P upgrade

S&P's upgrade to BBB- means Teva now holds investment-grade ratings from all three major agencies, capping a multi-month credit rehabilitation.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A gloved hand holds a white medical device with a needle positioned over a blue-draped patient in a brightly lit clinic room with a window.

Teva Pharmaceutical Industries has secured investment-grade status from all three major credit rating agencies after S&P Global Ratings upgraded its long-term issuer credit rating to BBB- from BB+, with a stable outlook. The move, announced on 4 September 2026, follows earlier upgrades from Fitch and Moody's, completing a sweep that Teva's management has framed as a validation of its multi-year financial turnaround.

S&P's rationale pointed to sustainable growth prospects underpinned by strong execution in branded products, stabilisation in the generics business, and a pipeline of late-stage assets. The agency did not release a fuller public commentary within the materials accompanying Teva's announcement.

Debt reduction and strategic pivot

Eli Kalif, Teva's chief financial officer, said the trio of upgrades in a few months "reflects the strong execution of our Pivot to Growth strategy and the meaningful progress we have made in reducing debt and strengthening our financial profile." He added that the milestone enhances the company's financial flexibility to invest in growth and deliver long-term value.

Teva entered the 2020s carrying substantial debt, much of it a legacy of its 2016 acquisition of Allergan's generics business. The company spent the subsequent years divesting non-core assets, renegotiating opioid litigation settlements, and restructuring its cost base. Reaching investment grade across all agencies is the clearest signal yet that those efforts have been recognised by the capital markets.

Market context and competitive positioning

For a company of Teva's scale, the practical consequences of investment-grade ratings are considerable. Access to lower-cost debt and a broader pool of institutional fixed-income buyers improves the terms on which Teva can refinance existing obligations or raise fresh capital for business development. In a generics industry that has faced prolonged pricing pressure from pharmacy benefit managers and group purchasing organisations, that financial headroom is a competitive differentiator.

Teva's peers in the large-cap generics and branded-generics space, including Viatris and Sandoz, have each navigated their own post-spin or post-restructuring credit trajectories in recent years. Teva's return to investment grade ahead of some comparators strengthens its hand in partnership negotiations and potential in-licensing deals as it pursues its stated ambition to grow the innovative side of its portfolio, particularly in neuroscience and immunology.

The company has flagged a pipeline of late-stage branded assets as a key growth driver. Investors will be watching for pipeline readouts and any business development activity that puts the restored financial flexibility to work. Near-term milestones, including regulatory submissions and Phase 3 data, will be central to whether the ratings trajectory continues upward or stabilises at current levels. The next formal agency review cycles will provide an early test of whether the stable outlooks convert into positive ones.

Sector

Topic

Geography